Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -479,743 | 287,259 | 214,985 | -10,783 | -60,400 |
| Depreciation Amortization | 31,936 | 11,454 | 46,688 | 51,296 | 47,654 |
| Income taxes - deferred | 341,729 | 911 | -290,516 | 0 | N/A |
| Accounts receivable | -13,170 | -47,674 | 47,595 | 45,088 | -96,687 |
| Accounts payable and accrued liabilities | -2,755 | -16,343 | -655 | 1,784 | -10,677 |
| Other Working Capital | -73,555 | -168,801 | 499,425 | 37,044 | -177,747 |
| Other Operating Activity | 231,450 | 278,821 | 85,384 | 49,720 | 185,752 |
| Operating Cash Flow | $35,892 | $345,627 | $602,906 | $174,149 | $-112,105 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 315,525 | 5,008 | -911,911 | -320,441 | 63,660 |
| PPE Investments | -35,120 | -30,905 | -13,608 | -34,764 | -7,107 |
| Purchase Of Investment | N/A | -10,000 | 0 | -2,500 | N/A |
| Sale Of Investment | N/A | N/A | N/A | 2,507 | 4,467 |
| Purchase Sale Intangibles | -5,928 | -5,377 | -4,044 | -3,093 | -4,421 |
| Other Investing Activity | -5,928 | -5,377 | -4,044 | -3,093 | -4,421 |
| Investing Cash Flow | $274,477 | $-41,274 | $-929,563 | $-358,291 | $56,599 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 97,000 | 0 | 59,750 | 4,000 |
| Debt Repayment | 0 | -108,684 | 0 | -3,599 | -7,066 |
| Common Stock Issued | 52,036 | 175,767 | 475,865 | 255,106 | 13,417 |
| Common Stock Repurchased | -90,548 | -34,392 | 0 | N/A | N/A |
| Other Financing Activity | -558,097 | -29,670 | 0 | -82,170 | 1,043 |
| Financing Cash Flow | $-596,609 | $100,021 | $475,865 | $229,087 | $11,394 |
| Exchange Rate Effect | 617 | 93 | -18 | N/A | N/A |
| Beginning Cash Position | 683,287 | 278,820 | 129,630 | 84,685 | 128,797 |
| End Cash Position | 397,664 | 683,287 | 278,820 | 129,630 | 84,685 |
| Net Cash Flow | $-285,623 | $404,467 | $149,190 | $44,945 | $-44,112 |
| Free Cash Flow | |||||
| Operating Cash Flow | 35,892 | 345,627 | 602,906 | 174,149 | -112,105 |
| Capital Expenditure | -35,120 | -30,905 | -13,608 | -34,764 | -7,107 |
| Free Cash Flow | 772 | 314,722 | 589,298 | 139,385 | -119,212 |